机构:[1]Department of Abdominal Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, P. R. China四川大学华西医院[2]Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P. R. China四川省肿瘤医院[3]Nankai University School of Medicine/Collaborative Innovation Center of Biotherapy, Tianjin 300071, P.R. China
Chemoresistance in cancer has previously been attributed to gene mutations or deficiency. Caspase mutations or Bax deficiency can lead to resistance to cancer drugs. We recently demonstrated that Bak initiates a caspase/Bax-independent cell death pathway. We show that Plumbagin ( PL) ( 5-hydroxy-2-methyl-1,4-napthoquinone), a medicinal plant-derived naphthoquinone that is known to have anti-tumor activity in a variety of models, induces caspase-independent cell death in HCT116 Bax knockout ( KO) or MCF-7 Bax knockdown ( KD) cells that express wildtype ( WT) Bak. The re-expression of Bax in HCT116 Bax KO cells fails to enhance the PL-induced cell death. Additionally, Bak knockdown by shRNA efficiently attenuates PL- induced cell death. These results suggest that PL- induced cell death depends primarily on Bak, not Bax, in these cells. Further experimentation demonstrated that p53 Ser15 phosphorylation and mitochondrial translocation mediated Bak activation and subsequent cell death. Knockdown of p53 or a p53 Ser15 mutant significantly inhibited p53 mitochondrial translocation and cell death. Furthermore, we found that Akt mediated p53 phosphorylation and the subsequent mitochondrial accumulation. Taken together, our data elaborate the role of Bak in caspase/ Bax- independent cell death and suggest that PL may be an effective agent for overcoming chemoresistance in cancer cells with dysfunctional caspases.
基金:
Natural Science Foundation of China (NSFC)National Natural Science Foundation of China [81272458]; Program for New Century Excellent Talents in University (NCET)Program for New Century Excellent Talents in University (NCET) [12-0381]; Sichuan Province Science and technology support [2014SZ0045]; Wu Jieping Medical Foundation clinical scientific research special fund [320.6750.13360]
第一作者机构:[1]Department of Abdominal Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, P. R. China